Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615238 | 0.87 | MAOB (0.55) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL5183124 | 0.83 | SRC (0.51) | SMN1; SMN2NPC1ALDH1A1KDM4EMEN1 | |
| SCHEMBL15189660 | 0.82 | MAOB (0.69) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL6399385 | 0.80 | MAPK1 (0.51) | PARP10SMN1; SMN2NPC1RAB9AHDAC3 | |
| SCHEMBL433676 | 0.79 | MAOB (0.65) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL834204 | 0.78 | SMN1; SMN2 (0.61) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL10699043 | 0.78 | CA1 (0.48) | ALDH1A1KDM4EMAPTADRB2ADRB1 | |
| SCHEMBL11809433 | 0.78 | ALDH1A1 (0.56) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL978502 | 0.77 | RAB9A (0.71) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL810045 | 0.77 | RAB9A (0.63) | MAOBNR4A2NR4A1NR4A3PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| CN-1471512-A | Geminally substituted alphavβ3Integrin antagonists | — | 2004-01-28 | — | — | CN | disclosed |
| EP-1313705-A1 | GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6531494-B1 | Gem-substituted αvβ3 antagonists | PHARMACIA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002018340-A1 | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | CACNG5, ITGAV, ITGA5 | MAOB 4632/4885NR4A2 2743/4885NR4A1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.